bms 1

BMS-1 (PD-1 PD-L1 inhibitor 1) is an inhibitor of the PD1-PD-L1 protein-protein interaction. It also acts as an immunomodulator. Programmed death ligand 1 (PD-L1) is a protein in humans that is encoded by the CD274 gene and the upregulation of PD-L1 allows Ys to evade the host immune system. High tumor expression of PD-L1 was associated with increased tumor aggressiveness and a 4.5-fold increased risk of death.

BMS 183920 is a potent Angiotensin II Receptor antagonist that improves improves Caco-2 cell permeability in vivo.

BMS 182874 hydrochloride is a nonpeptide endothelin (El) receptor antagonist.

BMS 182874 is an orally effective and highly selective endothelin receptor ETA antagonist with an IC50 value of 0.150 μM for ETA and a Ki value of 0.055 μM for ETA.BMS 182874 is able to reduce arterial pressure in a rat hypertension model induced by Deoxycorticosterone acetate. BMS 182874 was able to reduce Deoxycorticosterone-induced arterial pressure in a rat model of hypertension and can be used to study cardiovascular disease.

BMS 193885 is a selective and competitive neuropeptide Y(1) receptor antagonist with affinity of 3.3 nM.

BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.

BMS 195614 (BMS614) is a selective RARα antagonist. BMS 195614 can bind to the RARα subunit.

BMS 180742 is an exosite inhibitor of thrombin.

Bms 188107 is a calcium antagonist, it has cardioprotective effects.

BMS 199264 hydrochloride is the salt form of BMS 199264.BMS 199264 is a potent and selective inhibitor of mitochondrial F1F0 ATP hydrolase (IC50=0.5 μM) without affecting ATP synthetase, thus preventing ATP reduction to ameliorate cardiac necrosis during ischemia, and is commonly used in studies of the cardiovascular system.

BMS 180448 is a prototype mitochondrial ATP-sensitive K+ (Mitok (ATP)) channel opener with cardioprotective and vasodilating properties.

BMS 180680 is a novel catechol-containing monolactam antibacterial active agent, which is the most effective compound against many species of Enterobacteriaceae.

BMS-181101 is a novel antidepressant that has pharmacological characteristics as a serotonin reuptake inhibitor and a serotonin 5-HT receptor agonist.

BMS 182264 is a bio-active chemical.

BMS 186318 is a human immunodeficiency virus (HIV) protease inhibitor designed to examine the possibility of developing resistance when two protease inhibitors are used together in recombination.

BMS 187071 is a bio-active chemical.

BMS 188745 Potassium Salt inhibits the biosynthesis of the Staphylococcus aureus virulence factor staphyloxanthin via inhibition of dehydrosqualene synthase (CrtM).

BMS-202 (PD1-PDL1 inhibitor 2) is an inhibitor of the PD-1 (Programmed death- 1) PD-Ll (Programmed death-ligand 1) protein protein interaction.

Linrodostat (BMS-986205) is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).

Ixabepilone (Azaepothilone B) is an orally bioavailable microtubule inhibitor. It binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis.

BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.BMS-488043 is used for the treatment of immune disorders, infections, and genitourinary disorders, and can be used in the study of HIV infect

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1) programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1 PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1 PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

BMS-345541 (IKK Inhibitor III) is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM, respectively.

BMS-823778 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) for the study of type 2 diabetes.